Pharmaceutical services company Open Orphan said US diagnostics company Quotient had entered into an exclusive contract with subsidiary hVIVO to support Covid-19 antibody testing in the UK. The testing technology would be used by hVIVO to screen for SARS-CoV-2 antibodies. The MosaiQ COVID-19 Antibody Microarray was CE marked as of 1 May based on testing that demonstrated 100% sensitivity and 99.8% specificity, Open Orphan said. 'There is a clear demand for Covid-19 antibody testing and we will be making testing available both as a standalone offering and will also utilize the testing capability to screen volunteers for our industry leading range of human challenge studies to ensure no disruption to our clients,' executive chairman Cathal Friel said. At 9:24am: (LON:ORPH) share price was +2.6p at 13.2p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.